Abstract: A trailer (10) or container (11) includes a frame (12) having a central axis (14) spaced between rear wheels. A plurality of storage supports (20) are supported on the trailer frame, with each storage support supporting a plurality of objects thereon. A carriage assembly (24) rotates the plurality of storage supports. A powered drive (110) rotates the carriage assembly. A powered restrictor (120) limits rotational movement of a respective carriage support during transit. Flexible members 142 and 144 interconnect the drive member and driven members each mounted with respect to a storage support. The container may be transported on a motorized vehicle. A preferred tire support mechanism is provided for use when transporting tires.

Abstract: A method for reducing gastrointestinal inflammation, enhancing growth, or improving feed efficiency in a human or non-human animal is disclosed. The method involves administering to the animal an agent that can reduce the formation of the signal transduction complex of endotoxin, TLR4 and CD14 on the cellular surface of a cell in the gastrointestinal tract of the animal. In a preferred embodiment, an antibody against the extracellular domain of TLR4 or CD14 is used to reduce the formation of the complex. A composition that contains the antibody and an ingestible carrier is also disclosed. Further disclosed is a method for producing a peptide for enhancing growth, improving feed efficiency, or both in a human or non-human animal.

Abstract: A medical training device with an improved clam shell type torso arrangement. An improved two-piece tiltable head feature, including mechanical mounting structure for secure attachment of an improved lung bag or face shield. The head also includes an improved nose feature to provide a more realistic representation of nasal cartilage, and an improved neck assembly. Additionally, an electro-mechanical indicator device is provided to show real time feedback of the CPR compression rate being administered by a student on the training manikin of the present application. The feedback by the device may be provided preferably by visual indicators, but may also have, or alternatively have, audio indicators or signals, such as words or sounds, to indicate whether or not the student is compressing within the preferred rate range, and/or the degree of variance in the student's compression sequences.

Abstract: It is disclosed here that a protein with a heat-labile specific binding activity can be stabilized with a saccharide compound with regard to the binding activity. To heat-stabilize the protein, it is mixed with a saccharide compound in a liquid suspension and the suspension is then dried to produce a solid that contains the protein and the saccharide. The saccharide compounds that possess the protein heat-stabilization activity include monosaccharides, disaccharides, polysaccharides, alkylated monosaccharides, alkylated disaccharides, alkylated polysaccharides, monosaccharide alcohols and alkylated monosaccharide alcohols.

Abstract: Methods are disclosed for distinguishing whether an animal is experiencing a bacterial infection or a viral infection. One monitors breath taken from the animal over time to measure the relative amount of a first breath stable isotope to a second breath stable isotope therein over time. A quick change in the isotope ratios within several hours from the likely infection is indicative of a bacterial infection. A delayed change in the isotope ratios, followed by periodic repeated alterations in the ratios, is indicative of viral infection. The methods are particularly efficient when using cavity ringdown spectroscopy for the monitoring. They may be used for monitoring a patient already admitted to a hospital, or for monitoring a patient initially complaining of adverse symptoms, or for triage, or for collectively monitoring a population of animals.

Abstract: A method for improving animal body weight uniformity or for increasing animal carcass yield is disclosed. The method involves administering an agent to one or a group of animals wherein the agent can reduce bioavailability of a prostaglandin or leukotriene lipid precursor. In a preferred embodiment, the agent employed is an anti-PLA2 antibody.

Abstract: The invention is methods and related kits for diagnosing a disease state of cachexia by measuring biomarker profiles from a biological sample. Rapid measurement of early onset or progression of the disease in a subject is determined by measuring biomarker levels from the subject and optionally comparing the biomarker levels to a standard biomarker profile or metabolome phase portrait for the disease. The biomarkers measured in the assay and related kit for cachexia progression include biomarkers selected from the group consisting of lactate, citrate, formate, acetoacetate, 3-hydroxy butrate, alanine, glutamine, glutamate, valine, isoleucine leucine, thrionine, lysine, arginine, tyrosine, phenyl alanine, histidine and tryptophan.

Abstract: Methods and compositions for increasing antibody titer in egg yolks and for using the antibodies are disclosed.

Abstract: Methods are disclosed for distinguishing whether an animal is experiencing a bacterial infection or a viral infection. One monitors breath taken from the animal over time to measure the relative amount of a first breath stable isotope to a second breath stable isotope therein over time. A quick change in the isotope ratios within several hours from the likely infection is indicative of a bacterial infection. A delayed change in the isotope ratios, followed by periodic repeated alterations in the ratios, is indicative of viral infection. The methods are particularly efficient when using cavity ringdown spectroscopy for the monitoring. They may be used for monitoring a patient already admitted to a hospital, or for monitoring a patient initially complaining of adverse symptoms, or for triage, or for collectively monitoring a population of animals.

Abstract: A trailer (10) or container (11) includes a frame (12) having a central axis (14) spaced between rear wheels. A plurality of storage supports (20) are supported on the trailer frame, with each storage support supporting a plurality of objects thereon. A carriage assembly (24) rotates the plurality of storage supports. A powered drive (110) rotates the carriage assembly. A powered restrictor (120) limits rotational movement of a respective carriage support during transit. Flexible members 142 and 144 interconnect the drive member and driven members each mounted with respect to a storage support. The container may be transported on a motorized vehicle. A preferred tire support mechanism is provided for use when transporting tires.

Abstract: Methods and compositions for increasing antibody titer in egg yolks and for using the antibodies are disclosed.

Abstract: A trailer 10 includes a frame (12) having a central axis (14) spaced between rear wheels. A plurality of storage supports (20) are supported on the trailer frame, with each storage support supporting a plurality of objects thereon. A carriage assembly (24) rotates the plurality of storage supports. A powered drive (110) rotates the carriage assembly, and a powered brake (112) prohibits rotation of the carriage assembly when power is not applied to the motor. The power restrictor (120) limits axial movement of a respective carriage support during transit.

Abstract: A composition that contains a gamete or an embryo and animal white yolk is disclosed. Also disclosed are applications of the composition.

Abstract: The present invention provides a method of using conjugated nonadecadienoic acid (CNA), one of its derivatives, or a combination thereof to inhibit lipoprotein lipase activity associated with a cell, to control body fat in a human or non-human animal, to inhibit cyclooxygenase activity in a cell, to inhibit platelet aggregation in a human or non-human animal, and to prevent or treat a condition or disease related to platelet aggregation.

Abstract: A composition that contains a gamete or an embryo and animal white yolk is disclosed. Also disclosed are applications of the composition.

Abstract: A digestive system bezoar in a human or non-human animal susceptible to bezoar formation can be reduced in size by administering to the animal a food grade agent for emulsifying fat in an amount sufficient to reduce the size of the bezoar so that the bezoar can pass out of the animal's digestive system. In a similar method for preventing bezoar formation in a human or non-human animal susceptible to bezoar formation, a food grade agent for emulsifying fat can be administered to the animal in an amount sufficient to prevent formation of bezoars, or at least to prevent formation of bezoars larger than a size that becomes trapped in the animal's digestive system.

Abstract: A digestive system bezoar in a human or non-human animal susceptible to bezoar formation can be reduced in size by administering to the animal a food grade agent for emulsifying fat in an amount sufficient to reduce the size of the bezoar so that the bezoar can pass out of the animal's digestive system. In a similar method for preventing bezoar formation in a human or non-human animal susceptible to bezoar formation, a food grade agent for emulsifying fat can be administered to the animal in an amount sufficient to prevent formation of bezoars, or at least to prevent formation of bezoars larger than a size that becomes trapped in the animal's digestive system.

Abstract: The present invention provides a method of using conjugated nonadecadienoic acid (CNA), one of its derivatives, or a combination thereof to inhibit lipoprotein lipase activity associated with a cell, to control body fat in a human or non-human animal, to inhibit cyclooxygenase activity in a cell, to inhibit platelet aggregation in a human or non-human animal, and to prevent or treat a condition or disease related to platelet aggregation.

Abstract: A digestive system bezoar in a human or non-human animal susceptible to bezoar formation can be reduced in size by administering to the animal a food grade agent for emulsifying fat in an amount sufficient to reduce the size of the bezoar so that the bezoar can pass out of the animal's digestive system. In a similar method for preventing bezoar formation in a human or non-human animal susceptible to bezoar formation, a food grade agent for emulsifying fat can be administered to the animal in an amount sufficient to prevent formation of bezoars, or at least to prevent formation of bezoars larger than a size that becomes trapped in the animal's digestive system.